Submission declined on 30 October 2024 by -noah- (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: This article would be accepted onto Wikipedia if it had significant coverage by three independent, reliable sources. The only source provided that passes is the first source, the Le Temps article. Noah 💬 22:01, 30 October 2024 (UTC)
 | |
| Company type | Société Anonyme |
|---|---|
| Industry | Biopharmaceutical |
| Predecessor | CSL Vifor |
| Founded | Barcelona, (1930) |
| Headquarters | Geneva, Switzerland |
Area served | Worldwide |
Key people |
|
| Products | |
| Owner | Etienne Jornod (Executive Chairman & Co‑Owner) |
| Website | www |
OM Pharma is a Swiss multinational biopharmaceutical company headquartered in Geneva.
OM Pharma was originally founded in Barcelona in 1930 and later moved its headquarters to Geneva in 1937 under the leadership of Jean-René Ricard. In 2020, the company was acquired by Optimus Holding, led by Etienne Jornod, which committed to significant investments in its research and manufacturing capabilities.[1][2]
The company specialises in the development and commercialization of bacterial lysate-based products., aimed at preventing respiratory and urinary tract infections by training the immune system.[3] OM Pharma's pipeline focuses on future applications of lysates.
History
editIncorporation into CSL Vifor/Galenica
editIn 1970, the company re-established its main base of operations in Meyrin, where it continues to operate to this day. In 2009, the family-owned business was acquired by Galenica, part of the Vifor Pharma Group.[4]
Acquisition by Optimus Holding
editIn 2020, OM Pharma underwent a change in ownership when Optimus Holding, led by former Vifor Pharma Executive Chairman Etienne Jornod, acquired the company.[5]
This transaction re-established OM Pharma as an independent entity and included a commitment from Optimus Holding to invest over CHF 250 million into expanding the company's manufacturing and research capabilities.[6]
Structure and subsidiaries
editOM Pharma employs over 400 people, with its Global Headquarters and Biotech Campus located in Meyrin, Geneva, as well as an affiliate in Villars-sur-Glane, Fribourg.
The company also has a presence in Peru through an affiliate in Lima[7] and maintains a dedicated sales force in Central America, covering Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and the Dominican Republic.[8]
Additionally, OM Pharma has a presence in Shanghai to support its business partners across the Asia-Pacific region[9]
Partners
editOM Pharma has a network of global partners who market and distribute OM Pharma products. Partners range from local, family owned to multinational entities.
Research areas and products
editOM Pharma is known for the development of bacterial lysate products (OM-85 and OM-89) manufactured on its site in Meyrin, Geneva. The company also markets small molecules for the treatment of vascular diseases globally.
Globally marketed products
edit- Broncho Vaxom is an immunomodulator and bacterial lysate (OM-85) of 21 bacterial strains used for the prevention of recurrent respiratory tract infections.
- Uro Vaxom ® is an immunomodulator and bacterial lysate (OM-89) of 18 strains of Escherichia coli for the treatment and prevention of recurrent urinary tract infections.
- Dicynone® (etamsylate) is indicated in the treatment of capillary haemorrhages of different origins such as heavy menstrual bleeding or surgeries affecting highly vascularised tissues.
- Doxium® (calcium dobesilate) is used for the oral treatment of microangiopathies, signs of chronic venous insufficiency in the lower limbs, diabetic retinopathy and haemorrhoidal syndrome.
References
edit- ^ "Etienne Jornod achète une deuxième fois OM Pharma à Genève - Le Temps" (in French). 2020-09-18. ISSN 1423-3967. Retrieved 2024-10-30.
- ^ "Interview avec Etienne Jornod | Board Talk". Deloitte Switzerland (in Swiss French). Retrieved 2024-10-30.
- ^ Leo (2022-02-17). "List of the 3 largest chemical companies from Geneva (Canton)". Research Germany. Retrieved 2024-10-30.
- ^ BioAlps, Admin (2021-10-20). "BioAlps | 20 years of innovation | OM Pharma". BioAlps. Retrieved 2024-10-30.
- ^ Oviedo de Valeria, Jenny (1994-08-02). "chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/http://www.revista-educacion-matematica.org.mx/descargas/vol6/vol6-2/vol6-2-5.pdf". Educación matemática. 6 (2): 73–86. doi:10.24844/em0602.06. ISSN 2448-8089.
- ^ PricewaterhouseCoopers. "Vifor Pharma Group announces successful sale of OM Pharma to Optimus Holding Ltd". PwC. Retrieved 2024-10-30.
- ^ www.pmfarma.com https://www.pmfarma.com/app/noticias/53532-om-pharma-situa-su-filial-peruana-como-hub-regional-para-latinoamyrica. Retrieved 2024-10-30.
{{cite web}}: Missing or empty|title=(help) - ^ "Cartography of the Geneva Health Hub - Health field concerned - Pharmacy - OM Pharma". platform.genevahealthforum.com. Retrieved 2024-10-30.
- ^ "OM Pharma opens a new office in Shanghai - OM Pharma | OM Pharma". www.ompharma.com. Retrieved 2024-10-30.
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.